BofA Upgrades Candel Therapeutics to Buy as Prostate Cancer Filing Nears
Prostate data look filing-ready, cash is $201.6M, and analysts see ~66% upside.
/ 3 items
#CADL↓
Cantor Fitzgerald Calls Candel Therapeutics Deeply Undervalued – Overweight Rating Initiated
Cantor is very bullish on CADL, sees big undervaluation and CAN-2409 as a major drug with huge growth potential.
Stephens Initiates Overweight Coverage on Candel Therapeutics, Citing Transformative Pipeline and Limited Competition
Candel earned a $15 stock rating. Its key drug, CAN-2409, is seen as transformative because it improves current treatments.